CRN on Davis bill
This article was originally published in The Tan Sheet
Executive Summary
New legislation authorizing FDA to consider a dietary supplement's "unreasonable risk" in light of the level of its benefit would reverse the basic tenets of DSHEA, according to the Council for Responsible Nutrition. HR 3156, introduced June 30 by Rep. Carolyn Davis (D-Calif.), also would "codify FDA's risk/benefit rationale for removing ephedra from the market that was invalidated by the court in Nutraceutical v. Crawford," CRN maintains. The bill contains a provision establishing that in the absence of a sufficient benefit, the presence of even a relatively small risk of serious adverse health effect to a user may be considered unreasonable (1"The Tan Sheet" July 1, 2005, In Brief)...